Trial Profile
Demographics, clinical characteristics and treatment patterns of patients with multiple sclerosis who initiated ocrelizumab in USA, A real World study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2018
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 30 Oct 2018 New trial record
- 12 Oct 2018 Results (n=75) presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis